Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Insmed, Inc. (NASDAQ:INSM)

Key Points

• Representative Gilbert Ray Cisneros, Jr. sold between $1,001 and $15,000 in shares of Insmed, Inc. (NASDAQ:INSM) on July 7th, 2025, as disclosed in a filing.
• Insmed's quarterly earnings report showed a loss of ($1.70) earnings per share, missing analysts' estimates and reflecting a negative net margin of 259.82%.
• Analysts have a consensus rating of "Moderate Buy" for Insmed stock, with price targets ranging from $120.00 to $148.00 according to recent reports.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Insmed, Inc. (NASDAQ:INSM). In a filing disclosed on August 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insmed stock on July 7th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of W.R. Berkley NYSE: WRB on 7/31/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 7/31/2025.
• Purchased $1,001 - $15,000 in shares of Dayforce NYSE: DAY on 7/31/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 7/31/2025.
• Sold $1,001 - $15,000 in shares of Medpace NASDAQ: MEDP on 7/24/2025.
• Sold $1,001 - $15,000 in shares of Avantor NYSE: AVTR on 7/23/2025.
• Purchased $1,001 - $15,000 in shares of Revvity NYSE: RVTY on 7/23/2025.
• Purchased $1,001 - $15,000 in shares of Gulfport Energy NYSE: GPOR on 7/18/2025.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of PTC NASDAQ: PTC on 7/9/2025.

Insmed Stock Down 0.8%

Shares of NASDAQ INSM traded down $1.0590 during mid-day trading on Friday, hitting $131.5410. The company had a trading volume of 933,534 shares, compared to its average volume of 2,814,700. The company has a market capitalization of $27.81 billion, a PE ratio of -23.06 and a beta of 0.95. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $133.56. The business's 50-day simple moving average is $106.82 and its 200 day simple moving average is $85.31.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the previous year, the business posted ($1.94) earnings per share. The firm's revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on INSM. UBS Group raised their price target on Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Citigroup raised Insmed to a "buy" rating in a report on Tuesday, June 10th. The Goldman Sachs Group lifted their price target on shares of Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. HC Wainwright lifted their price objective on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Finally, Stifel Nicolaus lifted their price objective on Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $132.57.

Hedge Funds Weigh In On Insmed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. boosted its position in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 221 shares during the last quarter. Elequin Capital LP acquired a new stake in Insmed during the fourth quarter worth about $28,000. ORG Partners LLC raised its stake in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares during the period. Hilltop National Bank acquired a new stake in shares of Insmed in the second quarter valued at approximately $28,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Insmed in the second quarter valued at approximately $33,000.

Insider Buying and Selling

In related news, CEO William Lewis sold 6,865 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the transaction, the chief executive officer owned 233,924 shares in the company, valued at $30,035,841.60. This trade represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael Alexander Smith sold 933 shares of the firm's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $102.51, for a total transaction of $95,641.83. Following the transaction, the insider owned 66,394 shares in the company, valued at $6,806,048.94. This represents a 1.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 539,694 shares of company stock valued at $53,144,604 in the last ninety days. Insiders own 3.00% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.